Search Results - "Goldman, Jennifer D."

Commentary: Why Was Inhaled Insulin a Failure in the Market? by Oleck, Jacob, Kassam, Shahista, Goldman, Jennifer D

“…Just a few years shy of a century ago, a group of Canadian researchers discovered a viable method of extracting insulin, filling a large and critical gap in…”
Get full text

Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy by Goldman, Jennifer D

“…Type 2 diabetes mellitus (T2DM) is characterized by multiple metabolic abnormalities and current approaches to treatment involve a stepwise approach,…”
Get full text

Examining Delineated Competencies within Blended Hospital/Health System Pharmacy and General Medicine Advanced Pharmacy Practice Experiences by Prisco, Jennifer L, Murray, Yulia A, Eguale, Tewodros, Goldman, Jennifer D

“…In the United States, Doctor of Pharmacy (PharmD) programs are required to provide advanced pharmacy practice experiences (APPEs) in the core inpatient…”
Get full text

Important Factors in Remote Experiential Education by Prisco, Jennifer L, Goldman, Jennifer D, Eguale, Tewodros, Carace, Nicole

“…Onsite and in-person experiential education has been well established to prepare practice-ready healthcare professionals, such as pharmacists. From COVID-19,…”
Get full text

Optimizing Finerenone in People With Diabetes and Chronic Kidney Disease: An Opportunity for the Pharmacist by Goldman, Jennifer D.

“…Objective: This review aims to emphasize the role of pharmacists for optimization of evidence-based outcomes of finerenone in multidisciplinary kidney care…”
Get full text

Deniabetes by Goldman, Jennifer D

“…How can people sitting in front of us with symptoms, extensive clinical evidence, and laboratory confirmation deny their diagnosis of type 1 or type 2 diabetes…”
Get full text

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes by Goldman, Jennifer D.

“…What is known and objective People with type 2 diabetes (T2D) are at increased risk of cardiovascular disease (CVD), which in turn is associated with increased…”
Get full text

Teplizumab: The First Treatment to Delay the Progression of Type 1 Diabetes by Goldman, Jennifer D, Choi, Hailey

“…Type 1 diabetes is caused by autoimmune 3-cell destruction leading to the need for management with life-sustaining insulin. Typically, people are diagnosed…”
Get full text

Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit by Goldman, Jennifer D, Sangave, Nikhil

Get full text

Antihyperglycemic medications for cardiovascular disease risk reduction by Goldman, Jennifer D

“…In recognition of the substantial prevalence of cardiovascular disease-related comorbidities among patients with diabetes and the potential for some agents to…”
Get full text

Oral Superabsorbent Hydrogel (Plenity) for Weight Management by Pass, Alexa, Bialonczyk, Damian, Chiquette, Elaine, Goldman, Jennifer D.

“…Objective To describe the mechanism, clinical trial data, adverse effects, and potential role in therapy of an oral superabsorbent hydrogel (OSH) for weight…”
Get full text

A New Medical Probiotic Formulation for the Nutritional Management of Type 2 Diabetes by Goldman, Jennifer D., Camiel, Lana Dvorkin

“…Goldman and Carmiel discuss a novel probiotic formulation for the nutritional management of type 2 diabetes. According to the Centers for Disease Control and…”
Get full text

Transition of care to prevent recurrence after acute coronary syndrome: the critical role of the primary care provider and pharmacist by Goldman, Jennifer D., Harte, Francis M.

“…Despite therapeutic advances, patients with acute coronary syndrome (ACS) are at an increased long-term risk of recurrent cardiovascular events. This risk…”
Get full text

812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU), and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1st-Gen) BI (Glargine 100 U/mL [Gla-100] or Detemir [IDet 100 U/mL]) by EDELMAN, STEVEN, GOLDMAN, JENNIFER D., MALONE, DANIEL C., PREBLICK, RON, MUNAGA, KOVIDA, LI, XUAN, GILL, JASVINDER, GANGI, SUMANA

“…This retrospective observational analysis of the Optum Clinformatics database compared outcomes for adults (≥18y) with T2D who either continued treatment with…”
Get full text

Pen needle use patterns in an insured population with diabetes: U.S. retrospective claims analysis by Lupton, Laura, Sun, Xiaowu, Javadi, Pasha, Goldman, Jennifer D., Cornell, Susan, Fernandes, Joaquim, Kishorekumar, Sudha, Thach, Andrew, Sieradzan, Ray

“…People with diabetes who inject insulin with pen devices may reuse the pen needles (PNs), a practice that can cause PN tip deformity, breakage, and…”
Get full text

Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin by Martinez, Anthony, Goldman, Jennifer D.

Get full text

Anemia in CKD in Primary Care: Executive Summary by Brunton, Stephen, Fishbane, Steven, Goldman, Jennifer D, Wright, Eugene

“…Brunton et al discusses anemia in chronic kidney disease (CKD) in primary care. CKD is prevalent among people with diabetes. Many people with CKD suffer from…”
Get full text

Linagliptin-Induced Arthralgia by Nigro, Stefanie C, Goldman, Jennifer D

“…Goldman and Nigro asserts that a 71-year-old Caucasian man with a history of type 2 diabetes, stage 3 chronic kidney disease, hypertension, coronary artery…”
Get full text

Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin by Goldman, Jennifer D, Angueira-Serrano, Eugenio, Gonzalez, Jeffrey S, Pang, Christianne, Tait, Jacqueline, Edelman, Steven

“…Type 2 diabetes is a chronic, progressive disease, and its management results in a high emotional burden on patients. Eventually many patients require and can…”
Get full text

Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus by Goldman-Levine, Jennifer D.

“…The majority of patients with type 2 diabetes mellitus will eventually require combination therapy involving two or more agents to achieve their glycemic…”
Get full text